Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Rectal Neoplasms 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neuroendocrine Tumors 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

lutetium Lu 177 dotatate 5Specimen Handling 3Magnetic Resonance Spectroscopy 3pembrolizumab 2olaparib 2fludarabine 2cabozantinib 2X-Rays 2Phantoms, Imaging 2Cyclophosphamide 2tivozanib 1repotrectinib 1pazopanib 1fludarabine phosphate 1entrectinib 1belinostat 1atezolizumab 1aldesleukin 1Yttrium-90 1Tomography, X-Ray Computed 1Tomography, Emission-Computed, Single-Photon 1Temozolomide 1Single Photon Emission Computed Tomography Computed Tomography 1Salts 1Positron Emission Tomography Computed Tomography 1PT-100 dipeptide 1Octreotide 1Nivolumab 1Introns 1Interferon alpha-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Tomography, X-Ray Computed × 30 days × Clear all
NCT06122610 2026-05-15

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

University of Wisconsin, Madison

Phase 1 Recruiting
10 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡